NASDAQ: KIDS
Orthopediatrics Corp Stock

$24.91+0.80 (+3.32%)
Updated Feb 12, 2025
KIDS Price
$24.91
Fair Value Price
N/A
Market Cap
$603.22M
52 Week Low
$21.02
52 Week High
$35.99
P/E
-20.25x
P/B
1.63x
P/S
3.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$189.67M
Earnings
-$28.44M
Gross Margin
73.7%
Operating Margin
-16.57%
Profit Margin
-15%
Debt to Equity
0.32
Operating Cash Flow
-$31M
Beta
1.06
Next Earnings
Mar 4, 2025
Ex-Dividend
N/A
Next Dividend
N/A

KIDS Overview

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine KIDS's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
D
Momentum
C
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
D
KIDS
Ranked
#93 of 128

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$33.28A
$10.27A
$47.65A
View Top Medical Device Stocks

Be the first to know about important KIDS news, forecast changes, insider trades & much more!

KIDS News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KIDS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KIDS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KIDS is good value based on its book value relative to its share price (1.63x), compared to the US Medical Devices industry average (4.33x)
P/B vs Industry Valuation
KIDS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KIDS due diligence checks available for Premium users.

Valuation

KIDS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-20.25x
Industry
42.2x
Market
37.75x

KIDS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.63x
Industry
4.33x
KIDS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KIDS's financial health

Profit margin

Revenue
$54.6M
Net Income
-$7.9M
Profit Margin
-14.5%
KIDS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KIDS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$489.3M
Liabilities
$118.4M
Debt to equity
0.32
KIDS's short-term assets ($248.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KIDS's short-term assets ($248.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KIDS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KIDS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.3M
Investing
-$26.8M
Financing
$58.5M
KIDS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KIDS vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
KIDSC$603.22M+3.32%-20.25x1.63x
TMCIC$611.76M-1.80%-9.92x5.83x
VREXA$553.73M-0.44%-11.39x1.03x
CTKBB$669.82M0.00%0.01x1.74x
SIBNB$680.24M-2.23%-17.63x4.12x

Orthopediatrics Stock FAQ

What is Orthopediatrics's quote symbol?

(NASDAQ: KIDS) Orthopediatrics trades on the NASDAQ under the ticker symbol KIDS. Orthopediatrics stock quotes can also be displayed as NASDAQ: KIDS.

If you're new to stock investing, here's how to buy Orthopediatrics stock.

What is the 52 week high and low for Orthopediatrics (NASDAQ: KIDS)?

(NASDAQ: KIDS) Orthopediatrics's 52-week high was $35.99, and its 52-week low was $21.02. It is currently -30.79% from its 52-week high and 18.51% from its 52-week low.

How much is Orthopediatrics stock worth today?

(NASDAQ: KIDS) Orthopediatrics currently has 24,215,936 outstanding shares. With Orthopediatrics stock trading at $24.91 per share, the total value of Orthopediatrics stock (market capitalization) is $603.22M.

Orthopediatrics stock was originally listed at a price of $19.22 in Oct 12, 2017. If you had invested in Orthopediatrics stock at $19.22, your return over the last 7 years would have been 29.6%, for an annualized return of 3.77% (not including any dividends or dividend reinvestments).

How much is Orthopediatrics's stock price per share?

(NASDAQ: KIDS) Orthopediatrics stock price per share is $24.91 today (as of Feb 12, 2025).

What is Orthopediatrics's Market Cap?

(NASDAQ: KIDS) Orthopediatrics's market cap is $603.22M, as of Feb 13, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Orthopediatrics's market cap is calculated by multiplying KIDS's current stock price of $24.91 by KIDS's total outstanding shares of 24,215,936.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.